Page 3 - Taiwanese (TAIEX) Growth Pharmaceuticals & Biotech Stocks

UPDATED Aug 10, 2025

Discover Taiwanese Pharmaceuticals & Biotech Growth Stocks that are on the TAIEX. Sorted by forecasted growth, these Pharmaceuticals & Biotech Stocks have higher than expected earnings or sales growth compared to other companies.

134 companies
CompanyLast Price7D Return1Y ReturnMarket CapAnalysts TargetValuationGrowthDiv Yield
6808
3D Global Biotech
NT$45.80-5.2%27.6%NT$3.6bn/aPE38.9xn/a1.2%
4147
TaiMed Biologics
NT$77.40-6.7%-1.0%NT$21.1bNT$161.00PS34.8xn/an/a
6564
Enimmune
NT$16.852.1%-50.5%NT$1.2bn/aPS30.5xn/an/a
3176
Medigen Biotechnology
NT$30.90-0.3%-17.4%NT$4.3bn/aPS2.7xn/an/a
6704
Gwo Xi Stem Cell Applied Technology
NT$22.80-1.3%-28.7%NT$2.2bn/aPS12.9xn/an/a
6467
Taho Pharmaceuticals
NT$99.5015.8%n/aNT$5.1bn/aPB9.9xn/an/a
6620
Handa Pharmaceuticals
NT$82.100%1.1%NT$13.0bNT$200.00PE27.5xn/a1.8%
4130
Genovate Biotechnology
NT$18.400.5%-16.0%NT$2.1bn/aPE110.3xn/a0.5%
3716
Cenra
NT$34.400.7%n/aNT$5.0bn/aPE15.2xn/a2.9%
3164
GenMont Biotech Incorporation
NT$20.00-1.2%-11.7%NT$1.7bn/aPE110xn/a4.0%
6657
Energenesis BiomedicalLTD
NT$57.801.9%9.9%NT$5.1bn/aPS678.4xn/an/a
7729
Steminent Biotherapeutics
NT$33.5022.3%32.9%NT$1.9bn/an/an/an/a
6541
Tanvex BioPharma
NT$51.500.6%0.6%NT$12.3bn/aPS151.3xn/an/a
6661
Welgene BiotechLtd
NT$20.00-0.5%-30.3%NT$466.1mn/aPE209.4xn/a0%
7762
Pet Pharm Biotech
NT$63.205.5%104.9%NT$3.2bn/an/an/a0.3%
6733
BioGend Therapeutics
NT$29.952.2%-10.3%NT$3.7bNT$33.00PS19.1xn/an/a
1752
Nang Kuang Pharmaceutical
NT$35.501.3%-20.8%NT$3.6bn/aPE13.4xn/a4.5%
6696
Lin BioScience
NT$168.508.4%79.4%NT$13.9bn/aPB4.9xn/an/a
6662
BioLASCO Taiwan
NT$32.35-5.1%-11.1%NT$828.5mn/aPE18.4xn/a5.1%
4132
Golden Biotechnology
NT$11.50-4.6%-45.1%NT$1.9bn/aPS45.6xn/an/a
4157
TaiGen Biopharmaceuticals Holdings
NT$8.617.2%-39.6%NT$6.2bn/aPS40.8xn/an/a
6810
Bio Preventive Medicine
NT$26.65-4.3%-13.5%NT$1.3bn/an/an/an/a
4743
Oneness Biotech
NT$64.603.0%-54.8%NT$30.9bNT$308.00PS274.5xn/a0%
6785
Alar Pharmaceuticals
NT$180.0017.6%-3.7%NT$12.0bn/aPS1700.7xn/a0.1%
Page 3 of 6